The present invention generally relates to an electrochemical cell, or battery, and more particularly relates to an electrolyte for use in electrochemical cells.
Modern medical devices, such as defibrillators, pacemakers, neurostimulators, and drug delivery devices, have demanding power requirements. For example, defibrillator devices continuously monitor the electrical activity of a patient's heart, detect ventricular fibrillation, and in response, deliver appropriate electrical pulses, or shocks, to the heart to restore a normal heart beat. Typically, the pulses from a defibrillator are generated by capacitors and may need to be between 30 and 35 joules in order to achieve the desired effect. In order to deliver the pulses in a timely fashion, the capacitors must be charged in just a few seconds. Therefore, batteries used in such devices must have what is known as “high rate capability,” possess low self-discharge to have a sufficiently long useful life, and be highly reliable. Additionally, because such devices may be surgically implanted into the patient, the battery must be as small as possible.
Lithium batteries are now commonly used as power sources for such medical devices. These batteries, or electrochemical cells, generally include a lithium anode and a cathode which often contains carbon monofluoride and/or silver vanadium oxide. The anode and the cathode are typically enveloped in an electrolyte (e.g., an electrolytic solution) containing a solute (typically a lithium salt, such as LiAsF6) and a solvent mixture (e.g., propylene carbonate (PC), dimethoxyethane (DME), and/or diglyme (DG)).
During discharge, the lithium batteries typically experience a significant amount of swelling. As a result, the space made available for the batteries in the medical devices must be slightly larger than the normal, non-swollen size of the battery, thereby increasing the overall size of the devices. Additionally, as the amount of lithium salt in the electrolytic solution increases beyond the optimum concentration, the conductivity of the solution is adversely affected.
Accordingly, it is desirable to provide an electrochemical cell which experiences a reduced amount of swelling during discharge. In addition, it is desirable to provide an electrochemical cell with an electrolytic solution that provides improved conductivity. Furthermore, other desirable features and characteristics of the present invention will become apparent from the subsequent detailed description of the invention and the appended claims, taken in conjunction with the accompanying drawings and this background of the invention.
An electrochemical cell is provided with reduced swelling during operation. The electrochemical cell comprises a housing, an anode and a cathode within the housing, and an electrolytic solution within the housing and contacting the anode and the cathode, the electrolytic solution comprising a solute and a solvent, the solute comprising at least one of tetrafluoroborate and an organic cation.
The present invention will hereinafter be described in conjunction with the following drawing figures, wherein like numerals denote like elements, and
The following detailed description of the invention is merely exemplary in nature and is not intended to limit the invention or the application and uses of the invention. Furthermore, there is no intention to be bound by any theory presented in the preceding background of the invention or the following detailed description of the invention. It should also be noted that
Referring to
The electrode assembly 16 includes an elongated anode 30 and an elongated cathode 32 wound, or coiled, together such that the electrode assembly 16 has a size and shape that is similar to the size and shape of the electrode pocket 26 within the case liner 14. In one embodiment of the present invention, the anode 30 is made of lithium and the cathode 32 is made of porous, or fibrous, carbon monofluoride (CFx). As will be appreciated by one skilled in the art, the cathode may also include non-fibrous CFx, silver vanadium oxide (SVO), manganese dioxide (MnO2), copper vanadium oxide, vanadium oxides (such as V2O5), and lithium vanadium oxide (such as LixV3O8) and may be what is known as a “hybrid cathode.” Although not specifically illustrated, the anode 30 and the cathode 32 may be pressed onto a metal current collector, which may be made of, for example, nickel or titanium, and enveloped with a separator of microporous material such as polyethylene, polypropylene, or other suitable material. The electrode assembly 16 also includes anode connector tabs 34 and 36 connected to the anode 30 and cathode connector tabs 38 and 40 connected to the cathode 32. As shown in
Still referring to
The battery assembly 10 is assembled by inserting the coil insulator 18, the electrode assembly 16, and the case liner 14 into the electrode cavity 24 of the case 12, as indicated by the arrows in
Referring now to
As indicated by the arrows in
An electrolytic solution is then introduced into the electrode cavity 24 through the fill port 60 in the case cover 22 to envelope the components within the electrode cavity, including the anode and the cathode, to form an electrochemical cell. As will be appreciated by one skilled in the art, the electrolytic solution includes a solute and a solvent. Solvents used can be organic solvents such as, for example, 3-methyl-2-oxazolidone, sulfolane, tetrahydrofuran, methyl-substituted tetrahydrofuran, 1,3-dioxolane, propylene carbonate (PC), ethylene carbonate, diethyl carbonate (DEC), dimethyl carbonate (DMC), gamma-butyrolactone, ethylene glycol sulfite, dimethylsulfite, dimethyl sulfoxide or mixtures thereof and also, for example, low viscosity co-solvents such as dimethoxyethane (DME), diglyme (DG) and other similar solvents.
In one embodiment of the present invention, the solute includes first and second compounds. The first compound is a simple or double salt, or a mixture thereof, such as a lithium salt. Examples of such lithium salts are lithium hexafluoroarsenate (LiAsF6), lithium hexafluorophosphate (LiPF6), lithium imide (Li(CF3SO2)2N), lithium tris(trifluoromethane sulfonate) carbide (Li(CF3SO2)3C), lithium tetrafluoroborate (LiBF4), lithium triflate (LiCF3SO3), and lithium perchlorate (LiClO4). Preferably, the concentration of the first salt within the solvent is approximately 1.0 M.
The second compound, or additive, is a salt and, as is commonly understood, includes an anion and a cation. In a preferred embodiment of the present invention, the anion is tetrafluoroborate (BF4−). The cation in the second compound is an organic cation such as a quaternary amine (either an alkylamine or an arylamine, or a mixed amine). The alkylamine may be, for example, tetramethylammonium (TMA), tetraethylammonium (TEA), tetra(n- or iso-)propylammonium (TPA), and/or tetra(n- or t-)butylammonium (TBA). In one embodiment, the concentration of the second compound within the solvent is between 0.1 M and 1.5M, preferably approximately 1.0M.
In use, the battery assembly 10 illustrated in
Referring to
The addition of the second compound or salt minimizes the amount of swelling that is experienced by the cathode during discharge. Therefore, the battery assembly does not need to be constructed to allow for extra room for the battery assembly to swell during operation. Thus, the overall size of the battery assembly, as well as the particular medical device, is reduced. Another advantage is that the conductivity of the electrolytic solution is not compromised by the addition of additional salt. A further advantage is that the addition of the second compound helps to maintain a proper Li+ concentration in the electrolytic solution.
It should be understood that the battery assembly 10 described above is only one example of a battery which could utilize the additives described above. Other embodiments may include structures with different sizes and shapes and varying chemical compositions.
While at least one exemplary embodiment has been presented in the foregoing detailed description of the invention, it should be appreciated that a vast number of variations exist. It should also be appreciated that the exemplary embodiment or exemplary embodiments are only examples, and are not intended to limit the scope, applicability, or configuration of the invention in any way. Rather, the foregoing detailed description will provide those skilled in the art with a convenient road map for implementing an exemplary embodiment of the invention, it being understood that various changes may be made in the function and arrangement of elements described in an exemplary embodiment without departing from the scope of the invention as set forth in the appended claims and their legal equivalents.